The 172 total participants had a mean (SD) age of 75.7 (4.8) years, and 108 (62.8%) were women. 4 key findings →
Participants: 172 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Compared with placebo, the use of G. biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment. 3 key findings →
Participants: 1,545 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Six months of high-intensity aerobic exercise had sex-specific effects on cognition, glucose metabolism, and hypothalamic-pituitary-adrenal axis and trophic activity despite comparable gains in cardiorespiratory fitness and body fat reduction. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Cognitive training involving speed of cognitive processing has the potential to delay the diagnosis of ADRD. 1 key finding →
Design: randomized controlled trial Participants: 2,021 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
71/100
The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. 3 key findings →
Design: randomized controlled trial Participants: 749 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. 4 key findings →
Design: cohort study Participants: 2,929 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The intent-to-treat analysis indicated a favorable effect of GHRH on cognition (P=.03), which was comparable in adults with MCI and healthy older adults. 1 key finding →
Participants: 152 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
During follow-up 319 participants developed dementia (221 had AD). 4 key findings →
Design: cohort study Participants: 2,288 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
64/100
Our study has identified not only risk factors associated with functional decline but also the interactions among these factors. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In particular, systemic inflammation, vascular inflammation, and altered endothelial function may play roles in domain-specific cognitive decline of nondemented individuals. 1 key finding →
Design: randomized controlled trial Participants: 1,159 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The use of AC medication was associated with increased brain atrophy and dysfunction and clinical decline. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High BP accelerates gait slowing in well-functioning older adults over a long period of time, even for those who control their BP or develop hypertension later in life. 4 key findings →
Design: cohort study Participants: 2,733 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Vision difficulty and a larger friend network were negatively associated with adherence. 5 key findings →
Design: randomized controlled trial Participants: 191 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These results should be confirmed with a randomized clinical trial of a centrally active ACE inhibitor in the prevention of cognitive decline and dementia. 5 key findings →
Participants: 1,054 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
56/100
Our recruitment rate demonstrates the feasibility of cohort participants to wear two devices that measure sedentary time and physical activity. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 0.279). No adverse events were reported. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These results add to the body of evidence on the adverse impact of ambient air pollution on cognitive aging and brain health and provide new insights into the genetic and behavioral factors that may impact individual susceptibility. 4 key findings →
Participants: 4,821 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss significantly lowered performance on the verbal parts of the Mini-Mental State Examination. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These data show an individually varying complex convergence of subclinical diseases in the brain of older CN adults. 2 key findings →
Participants: 1,672 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research increasingly suggests that subjective cognitive decline (SCD) in older adults, in the absence of objective cognitive dysfunction or depression, may be a harbinger of non-normative cognitive decline and eventual progression to dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
General and central obesity trajectories beyond midlife with persistently high or increasing patterns were significantly associated with an increased risk of developing cognitive decline and dementia in late life. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia. 2 key findings →
Participants: 452 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multidomain interventions may benefit younger older adults or those with overly strict or lenient HbA1c control; however, these findings need confirmation in future studies. 3 key findings →
Participants: 531 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In an aging population with increasing incidence of dementia and cognitive impairment, strategies are needed to slow age-related decline and reduce disease-related cognitive impairment in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →